Want to contact a Washington, DC Baraclude lawyer? ...Get a free case evaluation from one of our Washington, DC Baraclude lawyers now.
Baraclude - News Articles
-
Monday, April 16, 2007
Medical News Today (press release), UK -
Bristol-Myers Squibb Company (NYSE: BMY) today announced data from a cohort of nucleoside-naive HBeAg-negative chronic hepatitis B patients (ETV-027/901, n=99). These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption ... -
Apr 13, 2007
Houston Chronicle, TX -
© 2007 AP. NEW YORK — Drug maker Bristol-Myers Squibb Co. said Friday its hepatitis B drug Baraclude was effective in retreating patients who had experienced recurrent levels of the virus. In a cohort study, 93 percent of patients who had ... -
Mar 14, 2007
Sarasota Herald-Tribune, FL -
Medicines for hepatitis B are entecavir, adefovir, lamivudine and interferon alpha. The newest medicine is telbivudine. Yes, there is a shot to prevent hepatitis B infection and, therefore, the carrier state. It's the hepatitis B vaccine. ... -
Monday, April 02, 2007
Medscape (subscription) -
Guidelines for managing HIV and chronic hepatitis B virus (HBV) coinfection include the recommendation for entecavir when treating HBV alone. ... -
Mar 13, 2007
Medscape (subscription) -
The second presentation involved some unexpected data concerning the use of entecavir in HIV/HBV-coinfected patients. Chloe Thio at the John Hopkins ... -
Mar 12, 2007
Johns Hopkins Gazette, MD -
Their findings demonstrate that treatment with entecavir leads to cross-resistance to other antiviral drugs used to treat the AIDS virus. ... -
Mar 15, 2007
Bay Area Reporter, CA -
The drug is entecavir (Baraclude), which was approved by the Food and Drug Administration in March 2005 and quickly became the drug of choice in treating ... -
Feb 28, 2007
Atlanta Journal Constitution (subscription), GA -
"The guidelines recommend entecavir as first-line therapy in HIV-infected patients who need their hepatitis B treated but not their HIV. That's no longer the case. With the data at present, the guidelines should be changed."As many as 400 million ... -
Mar 1, 2007
Newindpress (subscription), India -
"Our results show that entecavir is no different from any other that has been shown to be active against HIV - it breeds resistance rapidly, ... -
Mar 1, 2007
Pharmaceutical Business Review -
A Johns Hopkins study has found that the hepatitis B drug entecavir, widely used in patients co-infected with HIV, leads to cross-resistance to other antiviral AIDS drugs.Authors of the study have notified Bristol-Myers Squibb, which makes and sells entecavir under the brand name ...
-
Mar 2, 2007
Kaiser network.org, DC -
Hepatitis B Treatment and Resistance to Antiretrovirals: The hepatitis B drug entecavir might increase HIV-positive people's likelihood of developing ... -
Mar 1, 2007
Aidsmap, UK -
The hepatitis B drug entecavir (Baraclude) demonstrates activity against HIV and selects for mutations that confer resistance to certain antiretroviral medications, according to a study presented Wednesday at the Fourteenth Conference on Retroviruses and Opportunistic Infections in Los Angeles.Two ... -
Mar 7, 2007
exduco.net, Italy -
Their findings demonstrate that treatment with entecavir leads to cross-resistance to other antiviral drugs used to treat the AIDS virus. “Our results show that entecavir is no different from any other that has been shown to be active against HIV ... -
Mar 1, 2007
HealthCentral.com, VA -
Although many medications have this problem, entecavir (Baraclude) was thought to be different. "What that means is that [hepatitis B] patients, if they don't know they're HIV-positive, could start spreading drug-resistant HIV to other people," said Dr. Michael Horberg, director ... -
Mar 1, 2007
MedPage Today, NJ -
Explain to interested patients that entecavir (Baraclude) is recommended to treat hepatitis B in patients co-infected with HIV who are not on HIV therapy. Explain that entecavir may have activity against HIV, contrary to what had been thought, suggested by three case reports ... -
Feb 28, 2007
Facts and Comparisons, MO -
The revision is based on a case report in which human immunodeficiency virus (HIV) resistance was documented during treatment with Baraclude for chronic hepatitis B virus (HBV) infection in an HIV/HBV co-infected patient not simultaneously receiving highly active antiretroviral therapy (HAART). ... -
Mar 6, 2007
PharmaLive.com (press release), PA -
The Marketing Authorisation Holder for Baraclude has transmitted to the EMEA information regarding a case report in which the selection of a HIV variant containing the M184V resistance substitution was documented during Baraclude treatment in an HIV/HBV co-infected patient who was not simultaneously ... -
Feb 21, 2007
365Gay.com -
(Ottawa) The manufacturer of the antiviral drug Baraclude says the drug may be linked to the development of a treatment-resistant strain of HIV in one ... -
Feb 21, 2007
DG News -
OTTAWA, CANADA -- February 21, 2007 -- Health Canada is informing Canadians of new information submitted by the manufacturer of the antiviral drug Baraclude that suggests the drug may be linked to the development of a treatment-resistant strain of HIV in one patient ... -
Feb 21, 2007
CNW Telbec (Communiqués de presse), Canada -
21 /CNW Telbec/ - Health Canada is informing Canadians of new information submitted by the manufacturer of the antiviral drug Baraclude that suggests the ...
Want to contact a Washington, DC Baraclude lawyer? ...Get a free case evaluation from one of our Washington, DC Baraclude lawyers now.
Pages: Previous 1 2 3 4 5 6 Next
